Multiple Myeloma and Alkaline Phosphatase.
作者信息
Yavaşoğlu İrfan, Kadıköylü Gürhan, Bolaman Zahit
机构信息
Adnan Menderes University Faculty of Medicine, Division of Hematology, Aydın, Turkey Phone: +90-256-2120020 E-mail:
出版信息
Turk J Haematol. 2015 Jun;32(2):189-90. doi: 10.4274/tjh.2014.0495.
Abstract
摘要
相似文献
1
Multiple Myeloma and Alkaline Phosphatase.多发性骨髓瘤与碱性磷酸酶
Turk J Haematol. 2015 Jun;32(2):189-90. doi: 10.4274/tjh.2014.0495.
2
Leukocyte alkaline phosphatase levels in multiple myeloma.多发性骨髓瘤中的白细胞碱性磷酸酶水平
J Lab Clin Med. 1977 Jul;90(1):114-7.
3
Elevated alkaline phosphatase levels in multiple myeloma: fact or fiction.多发性骨髓瘤中碱性磷酸酶水平升高：事实还是虚构。
J Ky Med Assoc. 1967 Jan;65(1):36-8.
4
Treatment with bortezomib in multiple myeloma is associated with only a transient and brief increase of bone specific alkaline phosphatase.硼替佐米治疗多发性骨髓瘤仅与骨特异性碱性磷酸酶的短暂、短暂增加有关。
Leuk Res. 2012 Oct;36(10):1296-9. doi: 10.1016/j.leukres.2012.06.007. Epub 2012 Jun 29.
5
Immunophenotyping of myeloma cells with immunoalkaline phosphatase technique.采用免疫碱性磷酸酶技术对骨髓瘤细胞进行免疫表型分析。
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1986 Nov;19(4):258-62.
6
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.碱性磷酸酶对硼替佐米治疗的多发性骨髓瘤患者缓解及疾病进展时间的预测价值
Am J Hematol. 2007 Sep;82(9):831-3. doi: 10.1002/ajh.20961.
7
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.在接受卡非佐米治疗期间，碱性磷酸酶的变化与多发性骨髓瘤患者的最佳反应相关。
Eur J Haematol. 2011 Jun;86(6):484-7. doi: 10.1111/j.1600-0609.2011.01602.x.
8
Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.抗酒石酸酸性磷酸酶同工型5b：一种用于监测多发性骨髓瘤骨病的新型血清标志物。
Int J Cancer. 2003 Sep 1;106(3):455-7. doi: 10.1002/ijc.11247.
9
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.硼替佐米降低复发多发性骨髓瘤患者血清中Dickkopf-1和核因子-κB受体激活剂配体的浓度，并使骨重塑指标恢复正常。
Br J Haematol. 2006 Dec;135(5):688-92. doi: 10.1111/j.1365-2141.2006.06356.x.
10
High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation.
Leukemia. 2005 Jun;19(6):1102-3. doi: 10.1038/sj.leu.2403758.
本文引用的文献
1
Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options.接受不同治疗方案的多发性骨髓瘤患者的骨特异性碱性磷酸酶水平
Turk J Haematol. 2014 Dec 5;31(4):374-80. doi: 10.4274/tjh.2013.0004.
2
Vitamin D status may effect the skeletal complications of multiple myeloma.维生素D状态可能影响多发性骨髓瘤的骨骼并发症。
Am J Hematol. 2010 Apr;85(4):302-3. doi: 10.1002/ajh.21619.
3
Prevalence and significance of vitamin D deficiency in multiple myeloma patients.多发性骨髓瘤患者维生素D缺乏的患病率及意义
Br J Haematol. 2008 Jul;142(3):492-4. doi: 10.1111/j.1365-2141.2008.07214.x. Epub 2008 May 8.
4
Prevalence of Paget's disease of bone in Italy.意大利骨佩吉特病的患病率。
J Bone Miner Res. 2005 Oct;20(10):1845-50. doi: 10.1359/JBMR.050518. Epub 2005 May 31.
5
The elevated serum alkaline phosphatase--the chase that led to two endocrinopathies and one possible unifying diagnosis.
Eur J Endocrinol. 1999 Feb;140(2):143-7. doi: 10.1530/eje.0.1400143.
Zotero 插件